Group items tagged

NHS England has commissioned the Royal Pharmaceutical Society (RPS) to develop guidance that helps community and hospital pharmacy teams across Britain to reduce the impact of pharmacy services, pharmaceutical care and medicines on the environment. The RPS said the Greener Pharmacy Guidance will enable pharmacies to self-assess their impact against the standards, benchmark and improve through evidence-based activities and actions. "I'm delighted our strong commitment to helping pharmacy reduce its environmental impact can now be taken to the next level through developing guidance and accreditation for pharmacy teams," RPS president Professor Claire Anderson said. "Medicines account for 25 per cent of carbon emissions within the NHS and this initiative underscores our commitment to promoting sustainable healthcare and supporting the NHS's goal of achieving 'net zero' emissions by 2040." Peter Morgan, medicines assistant director at NHS England, commented: "Pharmacy staff are involved in the purchasing and dispensing of almost every medicine used in the NHS and the new Greener Pharmacy Guidance and Self-accreditation scheme will provide support for pharmacy professionals by outlining clear actions to deliver more environmentally sustainable pharmacy practices." The RPS said the guidance and digital self-assessment toolkit will integrate with carbon calculator tools to help pharmacy teams to measure their carbon footprint, action plan to reduce use of carbon and improve sustainability.

Community Pharmacy England (CPE) is seeking views from all community pharmacy owners about the pressures faced this autumn season. A survey has been launched as the "November Pre-Committee Opinion Poll" until 6 November to seek views from independents and non-Company Chemists' Association (CCA) members. The results of the poll will be sent to the head offices of CCA multiples next week for discussion at the November Committee Meeting. CPE confirmed: "The results of these polls and the outcomes of the meeting will be reported back to the sector afterwards. They said that the survey "will be used to feed into our ongoing work to press for an uplift to core funding by enhancing our evidence base of what pharmacy owners are experiencing."

Pharmacists globally are broadening their roles to support self-care, aiming to enhance patient health outcomes through increased contributions and proactive behaviours, according to a new report. However, significant barriers, including inadequate funding and limited access to patient records, impede the optimisation of self-care activities and outcomes improvement in this area, the International Pharmaceutical Federation (FIP) said in its report. The FIP report, titled 'Community Pharmacy Insights: Supporting the Need for Self-Care,' gathers insights from 238 respondents across 55 countries with the aim of providing evidence-based policy support for workforce development. Nearly all respondents (93.2 per cent) indicated that pharmacists should actively engage in providing self-care support, FIP said. Furthermore, 48.9 per cent supported the involvement of pharmacy technicians, while 39.2 per cent endorsed the participation of pharmacy assistants and other team members in offering self-care support.

Members of the Pharmacists' Defence Association (PDA) who have benefits in the Boots Pension Scheme have sought support from their union following the recent communications from the trustees about the removal of the option to retire at 60 without a reduced pension. The company claimed that retirement between 60-65 years old without a reduced pension was a discretionary benefit, and it has ended with the buy-in deal with Legal and General. However, PDA members believe there is insufficient evidence to fully support this claim, and therefore they are questioning whether this option should have been secured as part of the buy in and not ended with immediate effect. PDA Union national officer, Paul Moloney said: "Instead, we believe benefit statements issued to members, at the very least are contradictory, and clearly state that a full pension will be payable from a member's 60th birthday, with no reference to this benefit being discretionary and therefore subject to a regular review by the trustees. Instead, the benefit statements give the impression that an unreduced pension from 60 is a right with no indication that retirement plans should not be based on the benefit statements."

The Royal Pharmaceutical Society has appointed communications agency to lead a review into how it can develop and strengthen member participation. "We've appointed communications consultancy Luther Pendragon to carry out an independent review of the participation of members and of our communications concerning decisions we take on behalf of the profession through our Governance boards," the Society said in a statement on Tuesday (May 10). It added that review would examine how RPS members, elected members and stakeholders can feel engaged, informed and empowered to influence decisions about RPS policy and understand why decisions around organisational policy have been taken on their behalf by elected representatives. It will also ensure RPS decision-making processes are open and transparent with an emphasis on evidence-based decision making, and recommend ways elected members are enabled to be publicly accountable for decisions taken by the organisation at Board and Assembly level.

The Royal Pharmaceutical Society (RPS) has launched a partnership with the charity Marie Curie to develop professional standards in end of life care for community pharmacy. Available for pharmacy teams across the UK, the standards will provide a free, evidence-based framework to help community pharmacies self-assess and continuously improve their end of life and bereavement care for patients and carers. They will enable community pharmacy teams to work together to develop their own practice. RPS is setting up a professional standard steering group which will have community pharmacy experts, experts within the field of palliative and end of life care, lay members, and healthcare professionals who interact with community pharmacy. Elen Jones, director lead for palliative care work at RPS, said: "RPS has a long-term commitment, striving to ensure that people living with life-limiting conditions who are approaching the end of life have timely access to medicines and clinical support from a skilled pharmacy team. "The development of these standards, in partnership with Marie Curie, is a crucial step to support community pharmacy teams to undertake simple quality improvement measures and build upon the care they already provide to this group of patients and carers."

The National Pharmacy Association (NPA) and Royal Pharmaceutical Society (RPS) has been appointed as a core participant in the Covid-19 public inquiry. The independent public inquiry has been set up to examine the UK's response to and the impact of the Covid-19 pandemic and learn lessons to shape preparations for future pandemics. It is chaired by Baroness Heather Hallett, a former Court of Appeal judge. The NPA and RPS will be part of Module 3, which covers the impact of Covid-19 on healthcare systems across the United Kingdom. The preliminary hearing for that module takes place on Tuesday 28 February. This will give the association an opportunity to make opening and closing statements, consider evidence provided to the Inquiry and propose questions to be asked by the Inquiry of witnesses. NPA chief executive, Mark Lyonette, said: "This is an historic opportunity to place on record the achievements of community pharmacy during the pandemic and to ensure that the inquiry's recommendations are based in the practical realities faced by health workers such as our members.

Community pharmacies saved nearly 20,000 lives up to autumn 2021 by vaccinating people against the Covid-19, the National Pharmacy Association said based on a National Audit Office (NAO) report released on Friday (February 25). The report, having taken evidence from the NPA, highlighted that community pharmacies and GPs performed far beyond expectations in delivering the Covid-19 vaccine, as 71 per cent of jabs were administered by both healthcare providers till October-end, against an initial assumption of 56 per cent. The report cited UK Health Security Agency figures, which estimated that the programme overall prevented up to 128,000 deaths and 262,000 hospitalisations by September 24 and September 19, respectively. The estimated number is considerably higher, given the pivotal role played by pharmacies in this winter's phase of the vaccination programme, the NPA stated.

The new 'How to Involve and Engage Patients on Digital Health Tech Innovation' learning module has been created specifically to support the development and delivery of patient-centric technologies, at a time of critical digital transformation in the NHS. The foundation level module will be freely available at www.orcha-digitalhealthacademy.com and on the Health Education England NHS Learning Hub (learninghub.nhs.uk). No training previously exists on conducting effective patient and public involvement and engagement (PPIE), leading to wasted resource on unsuitable technologies at a time when the healthcare system simply cannot afford it. The module aims to educate innovators who are creating new technology, and the clinicians who are prescribing these solutions. Crucially, the module also provides valuable support to the 500 NHS clinicians who are on the Clinical Entrepreneur Programme. The module is an introduction to the first evidence-based framework for PPIE, launched by the University of Plymouth, the AHSN Network (the national voice of the 15 academic health science networks in England) and Boehringer Ingelheim UK & Ireland. It helps to fast-track learning for the EnACT principles described in the framework, outlining how to involve patients in product innovation and critical issues such as data privacy, intellectual property, inclusivity, reimbursement, useability, and recruitment of patients.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

In a recent announcement the Medicines and Healthcare products Regulatory Agency (MHRA) unveiled its strategic approach to artificial intelligence (AI), as it sets out to embrace the transformative potential of AI in healthcare regulation. Building upon the Government's white paper 'A pro-innovation approach to AI regulation', released in 2023, the MHRA outlined five key strategic principles guiding its adoption of AI. These principles encompass safety, security, and robustness; appropriate transparency and explainability; fairness, accountability, and governance; and contestability and redress. A science-led organization, the MHRA was tasked with providing an independent view of its approach to AI in medicine and science, aligning with a government white paper. Recognising its role in UK's goal to be a science and tech leader by 2030, MHRA is tasked to evaluate AI's opportunities and risks across regulatory, public service, and evidence-based decision-making area.

American pharmaceutical giant Pfizer has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for its medication Etrasimod, marketed as Velsipity, used to treat people with moderately to severely active ulcerative colitis. Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the lining of the large intestine (colon) and rectum. The approved recommended dose for Velsipity is one 2 mg tablet to be taken once daily. For the first three days, it is advised to take the medication with food, and subsequently, it can be taken daily either with or without food. According to the regulator, the approval of the medication is based on evidence from two clinical studies, which showed that 26 per cent of patients taking etrasimod achieved clinical remission after 12 weeks of treatment compared with 11 per cent of those receiving placebo. The studies included more than 740 patients aged 16 years and over for whom standard treatment or other treatments did not work well enough or could not be used.

The Competition and Markets Authority (CMA) has revoked its initial enforcement order imposed on Pharmacy2U Limited (Pharmacy2U) concerning the acquisition of Metabolic Healthcare Ltd (Lloyds Direct). In the revocation order issued on February 12, the regulator said its decision was "based on the evidence it has received in its assessment of the Merger to date." The CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on Pharmacy2U, P2U Holdings Limited, G Square Capital II L.P., G Square Healthcare Private Equity LLP (collectively, the Acquirer Group) and Lloyds Direct on 28 November 2023. It announced that it was considering "whether it is or may be the case that a relevant merger situation has been created and whether the creation of that situation has resulted or may be expected to result in a substantial lessening of competition in any market or markets in the United Kingdom (UK)."

Using Precision Medicine to Address Health Disparities is organized by eMedEvents Corporation. Efforts to solve, and overcome health disparities have yielded modest changes.

In a collaborative effort to combat the escalating threat of antimicrobial resistance (AMR), UWE Bristol and Bedminster Pharmacy have secured grant funding from the UKRI Regional Innovation Fund (RIF) for a groundbreaking 4-month project. This initiative aims to revolutionise antimicrobial stewardship (AMS) practices at the community pharmacy level, addressing the pressing need for evidence-based approaches in tackling AMR. With antibiotic misuse contributing significantly to the rise of AMR, the project underscores the vital role of community pharmacies in promoting responsible antibiotic use. Mr Ade Williams, Superintendent Pharmacist at Bedminster Pharmacy, emphasised the significance of this endeavour, stating:

Addiction is a complex and multifaceted condition that can significantly impact an individual's physical, emotional, and psychological well-being. Despite the strong desire to overcome addiction, many people struggle to achieve lasting recovery on their own. Professional help is crucial in addiction treatment because it offers specialized knowledge, comprehensive care, and evidence-based approaches tailored to each individual's needs. With the support of trained professionals, individuals are more likely to develop the skills and strategies necessary to achieve and maintain long-term sobriety. Understanding the Nature of Addiction Addiction is often misunderstood as merely a lack of willpower or moral failing. However, it is recognized by the medical community as a chronic disease that affects the brain's reward, motivation, and memory functions. These changes make it exceedingly challenging for individuals to control their substance use, even when facing adverse consequences. Through professional assessment, clinicians can identify the specific nature and extent of the addiction. This involves understanding the types of substances used, frequency, and the presence of co-occurring mental health conditions. Accurate diagnosis is essential for developing a tailored treatment plan that addresses all aspects of the individual's condition. The people behind https://healtreatmentcenters.com/resources/ note that there are many treatment centers and support groups available to help people with addiction. It takes the expertise of professionals to properly diagnose and treat addiction effectively.

Ultra Lightweight Wheelchair Folding Ultralight Wheelchairs is one of the lightest of all manual wheelchairs, compact size, easy to carry with its foldable nature. Folding Ultralight Wheelchair is ideal for both outdoor and indoor usage, and mostly used while travelling. Ultra Lightweight Wheelchair are quite similar to the lightweight wheelchairs but offer more adjustability for even more fine tuning to the user's needs. They are more expensive than the ultralight models but are basically ordered the same way with similar options. The difference is really most noticeable after delivery when all the adjustments become evident while setting the chair up. They are designed for users who are going to be using the chair daily for most of their mobility needs and spend many hours a day in the wheelchair but also lead a more active lifestyle and are looking for a little better performance.

Lightweight wheelchairs provide convenience and comfort to the user and caregiver alike and are often built using materials like aluminum and titanium alloy, while foldable wheelchairs allow for easy storage and transport. Merge the two styles, and got a great mobility aid that isn't a pain to lug around. Utilizing small wheels and lighter materials, transport wheelchairs can tip the scale at as little as 19 lbs, ideal for those looking for a highly portable option. Transport chairs also tend to be more affordable and offer the benefit of increased mobility without breaking the bank. This type of lightweight wheelchair is often referred to as a "transfer chair" and is typically used for shorter trips. Since it's geared towards storability and portability, it features four smaller wheels and dispenses with the larger, rear-mounted wheels that characterize standard wheelchairs. Its construction ensures that it's always foldable and portable, but does so at the expense of self-propulsion. Instead, a transport chair is built so that a caregiver can easily push the user. Transport wheelchairs or companion chairs are companion wheelchairs where the purpose is for a companion to push the user. Most transporters have swing-away leg rests, fixed armrests, and side panels. Instead of the usual 'large back - small front' wheels typical of most wheelchairs, light travel chairs have four small wheels providing much easier maneuverability of the chair. Karma Travel Wheelchair KM TV 20.2: Karma Travel Wheelchair KM TV 20.2 - 606 T-6 aircraft-grade aluminum-alloy frame provides incredible strength. Easy-to-fold in three seconds. Karma Travel Wheelchair KM TV 20.2 Features: Type: Travel Wheelchair. T-6 aircraft-grade aluminum. Secure brake improve safety. Padded flip back armrest. PU front caster & rear wheel. Karma Travel Wheelchair KM TV 20.2 Measurements: Weight: 8.9kg. Seat width: 39.5cm. Tyre: PU front casters and rear wheels. Capacity: 100

Adrenal Fatigue Solution relies on cutting-edge, evidence-based scientific research to bring you the best in natural healthcare.